PMID- 34471427
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 1759-720X (Print)
IS  - 1759-7218 (Electronic)
IS  - 1759-720X (Linking)
VI  - 13
DP  - 2021
TI  - Natural history and screening of interstitial lung disease in systemic autoimmune 
      rheumatic disorders.
PG  - 1759720X211037519
LID - 10.1177/1759720X211037519 [doi]
LID - 1759720X211037519
AB  - Interstitial lung disease (ILD) is a relatively frequent manifestation of 
      systemic autoimmune rheumatic disorders (SARDs), including systemic sclerosis 
      (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIM), 
      systemic lupus erythematosus (SLE), primary Sjogren's syndrome (pSS), and 
      anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Interstitial 
      pneumonia with autoimmune features (IPAF) has been proposed to describe patients 
      with ILD who have clinical or serological findings compatible with SARDs but they 
      are not sufficient for a definite diagnosis. ILD may present with different 
      patterns among patients with SARDs, but most commonly as nonspecific interstitial 
      pneumonia (NSIP), with the exception of RA and ANCA vasculitis that more often 
      present with usual interstitial pneumonia (UIP). The natural history of ILD is 
      quite variable, even among patients with the same SARD. It may present with 
      subclinical features following a slow progressively course or with acute 
      manifestations and clinically significant rapid progression leading to severe 
      deterioration of pulmonary function and respiratory failure. The radiographic 
      pattern of ILD, the extent of the disease, the baseline pulmonary function, the 
      pulmonary function deterioration rate over time and clinical variables related to 
      the primary SARD, such as age, sex and the clinical phenotype, are considered 
      prognostic factors for SARDs-ILD associated with adverse outcomes and increased 
      mortality. Different modalities can be employed for ILD detection including 
      clinical evaluation, pulmonary function tests, high resolution computed 
      tomography and novel techniques such as lung ultrasound and serum biomarkers. ILD 
      may determine the clinical outcome of SARDs, since it is associated with 
      significant morbidity and mortality and therefore screening of patients with 
      SARDs for ILD is of great clinical importance.
CI  - (c) The Author(s), 2021.
FAU - Panagopoulos, Panagiotis
AU  - Panagopoulos P
AUID- ORCID: 0000-0002-1630-7045
AD  - Department of Pathophysiology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Goules, Andreas
AU  - Goules A
AD  - Department of Pathophysiology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Hoffmann-Vold, Anna Maria
AU  - Hoffmann-Vold AM
AUID- ORCID: 0000-0001-6467-7422
AD  - Department of Rheumatology, Oslo University Hospital, Oslo, Norway.
FAU - Matteson, Eric L
AU  - Matteson EL
AD  - Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, 
      MN, USA.
FAU - Tzioufas, Athanasios
AU  - Tzioufas A
AD  - Department of Pathophysiology, School of Medicine, National and Kapodistrian 
      University of Athens, Mikras Asias 75, Athens 11527, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210828
PL  - England
TA  - Ther Adv Musculoskelet Dis
JT  - Therapeutic advances in musculoskeletal disease
JID - 101517322
PMC - PMC8404673
OTO - NOTNLM
OT  - Sjogren's syndrome
OT  - anti-synthetase syndrome
OT  - dermatomyositis
OT  - interstitial lung disease
OT  - interstitial pneumonia with autoimmune features
OT  - natural history
OT  - polymyositis
OT  - rheumatoid arthritis
OT  - screening
OT  - systemic lupus erythematosus
OT  - systemic sclerosis
OT  - vasculitis
COIS- Conflict of interest statement: The authors declared the following potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: E.M.: Consultant/advisory board, speaker 
      (Boehringer-Ingelheim); speaker: (Novartis); editor, writer (UpToDate). A.M.H.V. 
      has received research funding and/or consulting fees and/or other remuneration 
      from Actelion, Boehringer Ingelheim, Roche, Bayer, Merck Sharp & Dohme, ARXX, 
      Lilly and Medscape. P.P., A.G. and A.T. declare no conflict of interest.
EDAT- 2021/09/03 06:00
MHDA- 2021/09/03 06:01
PMCR- 2021/08/28
CRDT- 2021/09/02 06:55
PHST- 2021/04/10 00:00 [received]
PHST- 2021/07/19 00:00 [accepted]
PHST- 2021/09/02 06:55 [entrez]
PHST- 2021/09/03 06:00 [pubmed]
PHST- 2021/09/03 06:01 [medline]
PHST- 2021/08/28 00:00 [pmc-release]
AID - 10.1177_1759720X211037519 [pii]
AID - 10.1177/1759720X211037519 [doi]
PST - epublish
SO  - Ther Adv Musculoskelet Dis. 2021 Aug 28;13:1759720X211037519. doi: 
      10.1177/1759720X211037519. eCollection 2021.